Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of CM310 in seasonal allergic rhinitis
NCT05908721Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of stapokibart in seasonal allergic rhinitis (SAR), sponsored by Keymed Biosciences. Primary endpoint: Incidence of adverse events at Week 12. Started Aug 2023; status: completed.
02
Drugs
stapokibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT05908721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908721.